Last reviewed · How we verify
Botulinum Toxin Type A for Injection — Competitive Intelligence Brief
phase 3
Neurotoxin; neuromuscular blocking agent
SNAP-25 (synaptosome-associated protein of 25 kDa); acetylcholine release machinery
Neurology; Dermatology; Aesthetics
Small molecule
Live · refreshed every 30 min
Target snapshot
Botulinum Toxin Type A for Injection (Botulinum Toxin Type A for Injection) — Lanzhou Institute of Biological Products Co., Ltd. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Botulinum Toxin Type A for Injection TARGET | Botulinum Toxin Type A for Injection | Lanzhou Institute of Biological Products Co., Ltd | phase 3 | Neurotoxin; neuromuscular blocking agent | SNAP-25 (synaptosome-associated protein of 25 kDa); acetylcholine release machinery | |
| Botulinum Toxin Type A 900kDa | Botulinum Toxin Type A 900kDa | Allergan | marketed | Neurotoxin; acetylcholine release inhibitor | SNAP-25 (synaptosome-associated protein of 25 kDa) | |
| Botox infiltration | Botox infiltration | University Rovira i Virgili | marketed | Neurotoxin; botulinum toxin type A | SNARE complex (synaptosome-associated protein); acetylcholine release machinery | |
| Botulinum Toxin Type A (Botox) | Botulinum Toxin Type A (Botox) | University of Utah | marketed | Neurotoxin; neuromuscular blocking agent | SNAP-25 (synaptosome-associated protein of 25 kDa) | |
| Botulinum Toxin Type A 900kD | Botulinum Toxin Type A 900kD | Allergan | marketed | Neurotoxin; acetylcholine release inhibitor | SNAP-25 (synaptosome-associated protein of 25 kDa) | |
| Botulinum toxin A "Botox Cosmetics" | Botulinum toxin A "Botox Cosmetics" | Croma-Pharma GmbH | marketed | Neurotoxin; acetylcholine release inhibitor | SNARE complex (synaptosome-associated protein); acetylcholine release machinery | |
| Radiesse, Xeomin, Belotero | Radiesse, Xeomin, Belotero | Main Line Center for Laser Surgery | marketed | Dermal fillers and neurotoxin |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Neurotoxin; neuromuscular blocking agent class)
- Ivo Pitanguy Institute · 1 drug in this class
- Lanzhou Institute of Biological Products Co., Ltd · 1 drug in this class
- Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust · 1 drug in this class
- University of Utah · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Botulinum Toxin Type A for Injection CI watch — RSS
- Botulinum Toxin Type A for Injection CI watch — Atom
- Botulinum Toxin Type A for Injection CI watch — JSON
- Botulinum Toxin Type A for Injection alone — RSS
- Whole Neurotoxin; neuromuscular blocking agent class — RSS
Cite this brief
Drug Landscape (2026). Botulinum Toxin Type A for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-for-injection. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab